

JONATHAN W. BRUGGER, MD, MBA

Retina Care Consultants, P.A.
2401 University Parkway, Suite 205, Sarasota, FL 34243
(941) 351-1200

Board Certified ◦ Licenses in FL, NY, TN, MS, AR ◦ NPI: 1013172105

EDUCATION

Charles Retina Institute <i>Vitreoretinal Fellow</i> Memphis, TN	Jul 2018 – Jun 2020
New York Eye and Ear Infirmary <i>Ophthalmology Residency</i> New York, NY	Jul 2013 – Jun 2016
Liberty University <i>Masters of Business Administration, Concentration in Leadership</i> Lynchburg, VA	Jan 2010 – May 2012
Naval Undersea Medical Institute <i>Undersea Medical Officer, Radiation Health Officer</i> Groton, CT	Jan 2010 – Jun 2010
Naval Diving & Salvage Training Command <i>United States Navy Diver, Diving Medical Officer</i> Panama City, FL	Feb 2010 – Apr 2010
Naval Medical Center Portsmouth <i>Transitional Internship</i> Portsmouth, VA	Jun 2008 – Jun 2009
SUNY Upstate Medical University <i>Doctor of Medicine</i> Syracuse, NY	Aug 2004 – Jun 2008
University of South Florida <i>B.S. Biomedical Science; Biomedical Physics Minor</i> Tampa, FL	Aug 2000 – May 2004

PROFESSIONAL EXPERIENCE

Vitreoretinal Surgeon <i>Retina Care Consultants, Sarasota, FL</i> <ul style="list-style-type: none">• Diagnose, treat, and manage vitreoretinal diseases in the hospital and office setting• Perform vitreoretinal surgery	Jul 2020 – Present
--	--------------------

Clinical Instructor

Jul 2019 – Jul 2020

University of Tennessee Health Science Center, Hamilton Eye Institute, Memphis, TN

- Perform solo vitreoretinal surgery as a Junior Attending
- Staff Resident Retina Clinic and be on-call to the residents and faculty for retina/uveitis cases
- Provide lectures to the residents and assist with Grand Rounds presentations
- Surgical teaching to encompass both vitreoretinal and phacoemulsification procedures
- Retinopathy of Prematurity instructor to the Junior Vitreoretinal Fellows

Ophthalmic Consultant

Feb 2019 – Present

REGENXBIO Inc., Rockville, MD

- Supervise, instruct, and provide surgical support for training investigators
- Provide advice to the development of future surgical systems and indications
- Train protocol surgical supervisors and new porcine laboratory personnel

Staff Comprehensive Ophthalmologist

Jul 2016 – Jun 2018

Naval Medical Center Portsmouth, Portsmouth, VA

- Director of Surgical Logistics
- Refractive surgery (PRK and LASIK), cataract surgery with advanced intraocular lenses, Minimally Invasive Glaucoma Surgery (MIGS), eye screening for military readiness, duty physician, and medical student/intern/resident clinical teaching

Undersea Medical Officer / Diving Medical Officer

Jun 2010 – Jun 2013

Navy Experimental Diving Unit, Panama City, FL

- Multidisciplinary role of acute care, occupational, and hyperbaric medicine
- Institution Review Board Chairman (2012-2013), Vice Chair (2011-2012), Member (2010-2011)
- Completed the U.S. Navy Saturation Diving Course
- Experimental diver, principle and associate investigator, Assistant Medical Department Head, medical monitor for research protocols, international bends watch physician and coordinator, Ward Room treasurer, medical student/intern program director, and medical training officer

General Medical Officer

Jun 2009 – Dec 2009

Physical Medicine and Rehabilitation, NMCP, Portsmouth, VA

- Working with a board-certified PM&R physician, evaluated and treated a multitude of musculoskeletal injuries for six months and performed over 220 joint injections

Combat Casualty Care Course

Mar 2009

Fort Sam Houston, San Antonio, TX

- Trained for echelon I and II health service support elements in austere combat environments including nuclear, biological and chemical warfare. Trained in combat triage, casualty evacuation, combat health service support, and leadership in an operational setting

CLINICAL TRIALS

REGENXBIO RGX-314-001

Jul 2018 - Present

Sub-Investigator: Phase I, open-label, multiple-cohort, dose-escalation study to evaluate the long-term safety and tolerability of gene therapy with subretinal delivered RGX-314 in subjects with neovascular age-related macular degeneration (nAMD).

Charles Retina Institute. REGENXBIO.

Yosemite GR40349

Jul 2018 – Jun 2020

Sub-Investigator: Phase III, multicentered, randomized, double masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 (Faricimab) in patients with diabetic macular edema (DME).

Charles Retina Institute. Hoffmann-La Roche.

Tenaya GR40306

May 2019 – Jun 2020

Sub-Investigator: Phase III, multicentered, randomized, double masked, active comparator-controlled study to evaluate the efficacy, safety, durability, and pharmacokinetics of Faricimab administered at intervals as specified in the protocol, compared with Aflibercept (EYLEA) every eight weeks in participants with neovascular age-related macular degeneration (nAMD).

Charles Retina Institute. Hoffmann-La Roche.

Archway GR40548

Jul 2018 – Jun 2020

Sub-Investigator: Phase III, multicentered, randomized, visual assessor-masked, active comparator study of the efficacy, safety, and pharmacokinetics of the Port Delivery System (PDS) with Ranibizumab (Lucentis) compared with monthly Ranibizumab injections in neovascular age-related macular degeneration (nAMD).

Charles Retina Institute. Hoffmann-La Roche.

Portal GR40549

Mar 2019 – Jun 2020

Sub-Investigator: multicenter, open-label extension study to evaluate the long-term safety and tolerability of the Port Delivery System (PDS) with Ranibizumab 100 mg/ml refills administered every 24 weeks for approximately 144 weeks in participants with neovascular age-related macular degeneration (nAMD) who have completed either Phase II Study GX28228 (Ladder) or Phase III Study GR40548 (Archway).

Charles Retina Institute. Hoffmann-La Roche.

Kestrel CRTH258B2301

Jul 2018 – Jun 2020

Sub-Investigator: Phase III, multicentered, three-Arm, double masked study assessing the efficacy and safety of Brolocizumab (BEOVU) versus Aflibercept (EYLEA) in adult patients with visual impairment due to diabetic macular edema (DME).

Charles Retina Institute. Novartis Pharmaceuticals.

Merlin CRTH258AUS04

Feb 2019 – Jun 2020

Sub-Investigator: Phase IIIa, multicenter, randomized, double-masked, study to assess the safety and efficacy of Brolocizumab (BEOVU) 6mg dosed every four weeks compared to Aflibercept (EYLEA) 2mg dosed every four weeks in patients with neovascular age-related macular degeneration (nAMD) with persistent fluid despite frequent anti-Vascular Endothelial Growth Factor (VEGF) injections.

Charles Retina Institute. Novartis Pharmaceuticals.

Kingfisher CRTH258B2305

Oct 2019 – Jun 2020

Sub-Investigator: Phase III, multicentered, two-arm, randomized, double masked study assessing the efficacy and safety of Brolocizumab (BEOVU) every four weeks in adult patients with visual impairment due to diabetic macular edema (DME).

Charles Retina Institute. Novartis Pharmaceuticals.

MacTel NTMT-03-A

Mar 2019 – Jun 2020

Sub-Investigator: Phase III, multicenter, randomized, sham-controlled study to determine the safety and efficacy of Renexus surgical device implant in Macular Telangiectasia Type 2.

Charles Retina Institute. Neurotech Pharmaceuticals.

MacTel NHOR

Mar 2019 – Jun 2020

Sub-Investigator: A natural history observation and registry study of Macular Telangiectasia Type 2 who may agree to be contacted for inclusion in future clinical trials.

Charles Retina Institute. The Lowy Medical Research Institute.

Opthea OPT-302-1003

Mar 2019 – Jun 2020

Sub-Investigator: Phase Ib, multicenter, two-part, open label, sequential dose-escalation followed by a Phase IIa randomized, double-masked, dose expansion evaluating OPT-302 in combination with Aflibercept (EYLEA) in participants with persistent central-involved diabetic macular edema (DME).

Charles Retina Institute. Opthea Limited.

Raven CRTH258C2302

Fall 2019

Sub-Investigator: Phase III, multicenter, randomized, double masked, two-arm study to evaluate the efficacy and safety of Brovacizumab (BEOVU) in treatment of patients with macular edema secondary to central retinal vein occlusion (CRVO).

Charles Retina Institute. Novartis Pharmaceuticals.

RESEARCH & PUBLICATIONS

Hyperoxic Myopia: A Prospective Study of Twelve Divers with Six Hours of Exposure to 1.35ATM PO₂ for Five Consecutive Days

May 2015

Principle Investigator, Navy Experimental Diving Unit and New York Eye & Ear Infirmary of Mount Sinai, Poster at The Association for Research in Vision and Ophthalmology

Hyperoxic Myopia: A Case Series of Four Divers

Jun 2014

Principle Investigator, Navy Experimental Diving Unit and New York Eye & Ear Infirmary of Mount Sinai, Poster and Oral Presentation at Undersea and Hyperbaric Medical Society, Publish Pending

Health Survey of U.S. Navy Divers from 1960 to 1990: A First Look

Aug 2010 – May 2012

Co-Author, Navy Experimental Diving Unit, TA 06-25, NEDU TR 11-11, Sept 2011

Unmanned and Manned Testing of the Product Improvement

Dec 2010 – Mar 2011

Program's (PIP) Underwater Breathing Apparatus (UBA) Viper Very Shallow Water (VSW)

Principle Investigator, Navy Experimental Diving Unit, TL 11-01

PRE - PROFESSIONAL EXPERIENCE

Officer Indoctrination School

Jun 2005 – May 2005

United States Navy, Newport, RI

- Served as Drill Leader for the 50 members of the Foxtrot Division. Qualified as a third class swimmer, Damage Control certified, and fulfilled the mandatory Officer curriculum.

Officer Candidate School and Platoon Leadership Course

Jan 2001 – Aug 2003

United States Marine Corps, Quantico, VA

- Every month during college, reported for fitness testing, met weight/height requirements, and in the summer of 2001, completed the six week OCS/PLC at Marine Corps Base Quantico, VA.

Asst. Laboratory Researcher/ Laboratory Technician

Jan 2001 – Jul 2004

H. Lee Moffitt Cancer Research Center, Molecular Oncology, Tampa, FL

- Directly involved with research projects by assisting staff, creating digital figures, editing publication drafts, and managing the laboratory supplies.

Zamboni Driver and Closing Manager

Aug 1999 – Dec 2003

J. P. Igloo Ice and Inline Sports Complex, Ellenton, FL

- Maintained and operated the Zamboni ice resurfacing machines, supervised and conditioned ice surface, ice rink installation, and supervised the closing staff of the ice and inline facility.

Eagle Scout

April 2000 - Present

Boy Scouts of America

- After twelve years of Scouting, I earned the highest rank in Boy Scouts with 28 merit badges, Brotherhood in Order of the Arrow, and a 150+ hour Eagle Service Project that I organized.

HONORS & AWARDS

Military

- Promoted to Lieutenant Commander in 2013
- Ten years of Active Duty service
- Navy and Marine Corps Commendation Medal
- Navy and Marine Corps Achievement Medal (Gold Star in Lieu of Second Medal)
- Meritorious Unit Commendation Medal
- National Defense Service Medal
- Global War on Terrorism Service Medal
- Navy Rifle Marksmanship Ribbon
- Navy Expert Pistol Medal
- Saturation Diving Additional Qualification Designator (AQD)

Academic

- Vit-Buckle Society Fellows' Foray Surgical Video Travel Grant Awardee
- Featured Article: "An Officer and a Physician" Upstate Alumni Journal, Autumn 2006, pg: 14,15
- Humanism in Medicine Award Nominee
- Anatomy Prosection Team Member
- University of South Florida Green & Gold Merit Award
- Dean's List of Scholars
- Arts and Science Honor Society
- Golden Key International Honor Society
- National Society of Collegiate Scholars
- Povost's Scholars

Other

- 2003 Ice Hockey Champion, College Hockey South, Division III
- 1998 State Baseball Champion, Florida High School Athletic Association, Division 1A